SOX18 Inhibitor Compounds for Selective Protein-Partner Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to effectively inhibit SOX18 protein activity due to the lack of small molecules that can target its protein-protein binding domains, limiting therapeutic applications in conditions like cancer and vascular diseases.
Innovation Solution
Development of compounds that directly bind to or interact with the SOX18 protein, inhibiting its DNA-binding and protein partner recruitment, thereby modulating its activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecules are used to target transcription factors, then therapeutic applications are enabled, but the ability to target protein-protein binding domains is limited
Solution Approach 1:
The invention segments the SOX18 transcription factor into functional domains, specifically targeting the HMG-box DNA-binding domain and protein-protein interaction domains separately. This segmentation allows small molecules to be designed for specific functional regions, enabling targeted inhibition of protein-protein interactions without affecting other domains.
Solution Approach 2:
The patent employs peptide-based intermediaries that mimic natural protein partners of SOX18. These peptide intermediaries serve as competitive inhibitors by binding to SOX18's protein-protein interaction domains, preventing natural partners from binding while maintaining the ability to be delivered as small molecule conjugates.
2Object-affected harmful factors
If SOX18 activity is inhibited to treat cancer and vascular diseases, then therapeutic benefit is achieved, but lack of small molecules targeting protein-protein binding domains limits effectiveness
Solution Approach 1:
The invention creates composite therapeutic agents by conjugating peptide inhibitors with cell-permeable carriers or lipophilic moieties. This composite approach combines the specificity of peptide-protein interactions with the deliverability of small molecules, making the therapy both effective and manufacturable.
Solution Approach 2:
The patent modifies the physical-chemical parameters of peptide inhibitors by changing their lipophilicity, molecular weight, and permeability characteristics. These parameter changes transform otherwise non-permeable peptides into cell-permeable inhibitors that can be administered systemically and manufactured using standard pharmaceutical processes.
3Reliability
If compounds bind to SOX18 to inhibit DNA-binding and protein partner recruitment, then SOX18 activity is modulated, but selectivity against other transcription factors must be maintained
Solution Approach 1:
The invention applies local quality by designing inhibitors that target specific local regions of the SOX18 protein, particularly the protein-protein interaction domains distinct from the HMG-box DNA-binding domain. This localized targeting ensures high selectivity for SOX18 while sparing other transcription factors with different domain structures.
Solution Approach 2:
Instead of competing with DNA for binding to SOX18, the invention inverts the approach by competing with protein partners for binding to SOX18's protein-protein interaction domains. This inverted strategy provides selectivity because the protein-protein interaction interfaces are unique to SOX18 compared to other transcription factors.
Data Source
AI summary
Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.